New Strategic Collaboration | J&J Vision – Menicon
Through the partnership, Menicon will produce contact lenses with the potential to manage or even stop the worsening of nearsightedness in children ages 12 and under, and J&J will distribute the contacts around the world.
Research has proven that multifocal contact lenses, which combine different lens powers and are typically prescribed to wearers over the age of 40, can help slow down the progression of nearsightedness in children as young as seven years old.
Following the 2019 launch of the Menicon Bloom Myopia Control Management System in Europe, this collaboration will further strengthen Menicon’s commitment to help society combat the rising Myopia epidemic.
Myopia, or nearsightedness, has traditionally been viewed as an ocular inconvenience, once associated with scholars and those who pursued a predominantly indoor and education driven path.
Myopia treatment has typically involved usage of optical devices such as spectacles or contact lenses and its purpose, simply to correct the patient’s vision.
Modern myopia, however is an aggressively evolving disease and is projected to affect half the world’s population over the coming three decades. The most vulnerable to this disease in our society are children in which myopia progression is impacting their prospective visual and health outcomes due to increased risks of sight-threatening ocular pathologies, such as retinal detachments.
”Epidemiological evidence from all around the globe continues to show the remarkable increase in the percentage of children and young adults developing myopia, and the earlier age at which myopia starts,” said Professor Lyndon Jones, DSc, PhD, FCOptom.
This global epidemic comes with substantial risks of vision loss later in life and continued education on the importance of early intervention to manage the progression of myopia and the development of novel methods to reduce it have never been more important.
As part of the collaboration, Johnson & Johnson Vision will focus on expanding availability of the lenses around the world. Menicon will develop and manufacture the therapeutic contact lenses to manage the progression of myopia in children while continuing to support its current and new customers.
“Menicon has a long history of safety and innovation in the contact lens field and we continue to explore and invest in new ways to positively impact our patients” lives said Dr. Hidenari Tanaka, President, Menicon Co. Ltd.
“Our partnership with Johnson & Johnson is a wonderful opportunity to expand and realize our potential to effectively address the progression of myopia in children worldwide. A strategic collaboration such as this will be beneficial, particularly with an incredible company that shares our vision for the future, our high standards for safety and our common core values.”